Background
==========

For centuries, it has been hypothesised and debated that a mind-body interaction exists. Over time, an evidence base has grown to support this notion, yet an incomplete understanding prevails \[[@B1],[@B2]\]. Rates of depression and anxiety are generally higher among the physically ill than in the general population; however, results vary according to the type and severity of the chronic disease and methods of ascertainment \[[@B3],[@B4]\].

Within clinical samples, patients with depression have been found to have a significantly higher number of somatic symptoms \[[@B5]\] and a higher risk of chronic diseases \[[@B6]-[@B8]\], such as coronary heart disease \[[@B9],[@B10]\], congestive heart failure \[[@B11]\], stroke and dementia \[[@B12]\], diabetes \[[@B13],[@B14]\], gastro oesophageal reflux disease (GORD) \[[@B15]\], osteoarthritis and rheumatoid arthritis \[[@B16]\], psoriasis \[[@B17]\], cancer \[[@B18]\], neurological disorders \[[@B19]\], pulmonary disease \[[@B20]\], liver disease \[[@B21]\], thyroid disorders \[[@B22]\] and asthma \[[@B23],[@B24]\], as well as non-specific syndromes such as obesity \[[@B25]\], anaemia \[[@B26]\], renal dysfunction \[[@B27]\], chronic fatigue syndrome \[[@B28]\], chronic headaches \[[@B24]\], and chronic pain \[[@B29]\]. The strength of the association as well as the extent of the evidence varies for each medical condition.

Similarly, anxiety disxorders, have been shown to be related to several medical conditions, such as cardiovascular disease \[[@B30]\], cancer \[[@B18]\], obesity \[[@B31]\] and other metabolic disorders \[[@B32]\], irritable bowel syndrome \[[@B33]\], gastrointestinal problems \[[@B34]\], GORD \[[@B15]\], thyroid disorders \[[@B35]\], psoriasis \[[@B17]\] and a higher number of medical symptoms \[[@B36]\]. In addition, as recently reviewed by Culpepper and colleagues, migraine and chronic pain, diabetes, peptic ulcer, arthritis and pulmonary disease are also associated \[[@B2]\].

The co-occurrence of mood or anxiety disorders and physical illness worsens the impact of symptom burden \[[@B36]\], impacts disease course, links to the deteriorating patient's health status and functioning \[[@B7],[@B37]\], affects medication response and treatment adherence \[[@B38]\], and increases the risk of complications \[[@B39]\] and even death \[[@B37]\]. Moreover, the comorbidity between mental and physical illness is relevant in terms of role impairment and work performance \[[@B24]\], as well as quality of life and health service use and costs \[[@B40]\].

The causal pathway between comorbid mental and physical illness is complex and remains unclear. It has been suggested that the bi-directionality of this relationship may involve several mechanisms \[[@B41],[@B42]\] including biological (for example, increased pro-inflammatory cytokines, hypothalamic-pituitary axis deregulation, autonomic nervous system dysfunction, serotonin depletion, metabolic, immune and endocrine changes) \[[@B43]\], psychological (for example, behavioural, psychodynamic and cognitive factors) \[[@B44]\] and social (for example, impaired social support, loneliness, and social disengagement) \[[@B45]\]. Furthermore, psychotropic medication use has been linked to a higher incidence of an array of health outcomes, including diabetes, falls and bleeding, osteoporosis, and sudden cardiac death \[[@B46]-[@B48]\].

Enhancing the quality of care for those with mental illness not only can improve mood and anxiety symptoms, but also physical health in patients with comorbid mental and physical illness \[[@B49]\]. Furthermore, treatment for these disorders may influence each other \[[@B50]\]. Thus, estimating the prevalence and understanding the association between mood and anxiety disorders and physical illness is important in order to make more accurate diagnoses and to provide integrated and effective treatment, with regard to syndrome reciprocal influences and medication interactions. Given these data, we aimed to describe the relationship between comorbid mental and physical illness in a large, representative sample of men residing in Australia, utilising structured clinical interviews, medical records, and clinical and self-reported data collected as part of the Geelong Osteoporosis Study (GOS) \[[@B51]\].

Methods
=======

Participants
------------

Data were derived from the GOS male cohort, a study originally designed to investigate the epidemiology of osteoporosis in Australia. Originally, an age-stratified, population-based sample of adult men (n = 1,540; response 67%, 20 to 97 years old) was randomly-selected from the Australian Electoral Commission (AEC) rolls for the Barwon Statistical Division between 2001 and 2006. The Barwon Statistical Division is situated in South-Eastern Australia, comprising both rural and urban communities. Further details of the study have been published elsewhere \[[@B51]\].

Of those invited to participate in the five-year follow-up study (n = 1,540), 141 had died, 41 had left the study region, 16 were unable to provide written informed consent, 139 were not able to be contacted and 225 declined to participate resulting in 978 participants (81% of the eligible baseline sample). For this analyses, those who did not undergo psychiatric assessment (n = 17) or provide medical information (n = 19) were excluded, resulting in a final sample of 942 eligible men. This study was approved by the Barwon Health Human Research Ethics Committee and written informed consent was obtained from all participants.

Assessments
-----------

### Psychiatric measures

The Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) Research Version, Non-patient edition (SCID-I/NP) \[[@B52]\] was used to identify those who had ever experienced a mood disorder, including major depressive disorder, bipolar disorder (types I and II), dysthymia, minor depression, mood disorder due to general medical condition (GMC) and substance-induced mood disorder; and/or an anxiety disorder including panic disorder, agoraphobia, social phobia, specific phobia, obsessive compulsive disorder, generalised anxiety disorder, anxiety disorder due to a medical condition, substance-induced anxiety disorder or anxiety disorder not otherwise specified. All interviews were conducted by personnel with qualifications in psychology, who were trained using live and videotaped interviews under the supervision of a psychiatrist.

### Clinical measures

Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer and body weight was measured to the nearest 0.1 kg using electronic scales. Body mass index (BMI; kg/m^2^) was calculated from these measurements.

Lumbar spine and femoral neck bone mineral density (BMD) was measured by dual energy X-ray absorptiometry (DXA) using GE Lunar Prodigy (Prodigy GE Lunar Madison, WI, USA). Long term stability of the machine was tested three times weekly by scanning an anthropomorphic phantom (Hologic). Low bone mass was classified according to the World Health Organisation definition; one or more standard deviations below the young normal mean at the femoral neck or spine (L2-L4, posterior-anterior projection) \[[@B53]\].

### Medical conditions

The presence of medical conditions (lifetime) was self-reported and confirmed by medical records, medication use or clinical data, where possible. Musculoskeletal disease was defined by low BMD or self-reported osteoarthritis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, muscle disease or weakness, low trauma fracture, or self-reported or medicated gout (agents used in gout or hyperuricaemia). Thyroid disorders included self-reported or medicated (thyroid hormones and anti-thyroid agents) hyperthyroidism, hypothyroidism, Graves' disease, Hashimoto's disease, thyroiditis and other unspecified thyroid conditions. Metabolic risk factors included a diagnosis of diabetes, defined by self-report or current medication use (oral hypoglycaemic agents and insulin preparations), obesity defined by a BMI \>30 kg/m^2^\[[@B54]\], self-reported or medicated hypercholesterolemia (use of cholesterol-lowering agents) and hypertension. Hypertension was characterised by a combination of self-report and current medication use (antihypertensive, beta-adrenergic blocking agents and diuretics) or a systolic blood pressure of \>140 mmHg or diastolic blood pressure of \>90 mmHg. Diagnosis of GORD was based on self-report as were gastrointestinal diseases which include peptic ulcer, chronic gastritis and causes of malabsorption, such as pancreatitis, gastric surgery, chronic diarrhoea, irritable bowel syndrome, inflammatory bowel syndrome and coeliac disease. Cardiovascular disease was defined by a diagnosis of hypertension (as detailed above) or a combination of self-reported or medicated (beta-adrenergic blocking agents, diuretics, anti-arrhythmic, anti-angina, cardiac inotropic agents, adrenergic stimulants, other cardiovascular agents) stroke, transient ischaemic accident (TIA), ischaemic cardiomyopathy, arrhythmia and valve and vascular diseases. Syncope and seizures included self-reported epilepsy, blackouts, fainting and dizzy spells. Self-reported migraine and other recurrent headaches were grouped together. Lifetime pulmonary disease included self-reported asthma, emphysema and chronic bronchitis. Psoriasis was defined by self-report. Liver disease diagnosis, including fatty liver, hepatitis, cirrhosis and liver failure, was also based on self-report. Cancer was defined as any malignant tumour including non-melanoma skin cancer. High medical burden was classified as a diagnosis of three or more conditions listed above.

### Other measures

Smoking status, medication use and physical activity level were obtained by self-report \[[@B51]\]. Reported medication use was cross-referenced with the participants' list of medications or containers and was considered current if the participants reported use at the time of assessment. Men were classified as active if they participated in light to vigorous activity on a regular basis. Alcohol consumption (average grams consumed daily over a 12 month period) was determined by a validated food frequency questionnaire \[[@B55]\]. Tobacco smoking was documented and grouped as current or not. In order to determine socioeconomic status (SES), residential addresses were matched to the corresponding Australian Bureau of Statistics (ABS) Census Collection District (CCD). ABS software was used to determine the Socio-Economic Index for Areas (SEIFA) from the 2006 ABS Census data. SEIFA values summarize the characteristics of subjects within an area, thereby providing a single measure to rank the level of disadvantage at the area level, not of the individual subject. SEIFA values indicate the level of advantage or disadvantage within each CCD, small geographic areas that incorporate approximately 250 houses \[[@B56]\]. These values inform the Index of Relative Socioeconomic Advantage/Disadvantage (IRSAD), which accounts for various socioeconomic parameters including high and low income, educational attainment ranging from no qualifications to a tertiary degree or higher, the type of occupation from unskilled employment to professional positions, and some measure of wealth (such as owning a car, or number of bedrooms in a dwelling). The relative SES of participants was ascertained by categorizing the sample into quintiles based on cutpoints for the study region \[[@B57]-[@B59]\].

Statistical analysis
--------------------

Differences in characteristics between those with and without mood and anxiety disorders were compared using chi-square analyses for discrete variables and Mann--Whitney for non-parametric continuous variables. Logistic regression was used to calculate odds ratios (OR) with 95% confidence interval (95% CI) of lifetime medical conditions for those with lifetime mood/anxiety disorders in comparison to those with no mood/anxiety disorder. Models were adjusted for age (model I) and then for age, BMI, SES, physical activity, alcohol consumption and smoking status (model II). Interactions between exposure variables were examined. Each analysis was performed with and without participants with mood disorders due to GMC; no differences in outcome were detected, therefore, those with mood disorder due to GMC were included in all analyses. Values of *P* \<0.05 were accepted as significant (including interaction terms). Statistical analyses were performed using Minitab (version 16; Minitab, State College, PA, USA).

Results
=======

A total of 160 men (17%) had a lifetime history of mood disorder, of which 139 (86.9%) were identified with major depressive disorder, 10 (6.3%) dysthymia, 9 (5.6%) minor depression, 3 (1.9%) bipolar disorder, 3 (1.9%) mood disorder due to a GMC and 2 (1.3%) substance induced mood disorder. Of the 60 participants (12.2%) with a history of anxiety disorder, 23 (38.3%) met criteria for panic disorder, 15 (25%) post-traumatic stress disorder, 7 (11.7%) specific phobia, 6 (10%) social phobia, 5 (8.3%) generalized anxiety disorder, 5 (8.3%) obsessive compulsive disorder and 3 (5%) anxiety disorder not otherwise specified. Participants with a history of mood or anxiety disorder were younger than those without; otherwise the groups were similar (Table [1](#T1){ref-type="table"}).

###### 

Characteristics for the total group and men with or without lifetime history of mood disorder and anxiety disorder

                                                                    **Mood disorder**   **Anxiety disorder**                                                                      
  ------------------------------ --------------------------------- ------------------- ---------------------- ------------- ------------------- ------------------- ------------- -------
  Age at interview (years)       59.3 (45.7, 73.2)                  52.8 (42.6, 64.4)    60.9 (46.9, 75.4)       \<0.001     56.2 (41.1, 64.3)   59.9 (46.0, 74.0)      0.013     
  Body mass index (kg/m^2^)      27.1 (24.7, 29.6)                  27.1 (24.6, 29.6)    27.1 (24.8, 29.8)        0.671      27.7 (25.1, 30.3)   27.1 (24.6, 29.6)      0.257     
  Socioeconomic status (IRSAD)   Quintile 1 (most disadvantaged)       153 (16.2%)           24 (15.0%)        129 (16.5%)         0.581             6 (10.0%)       147 (16.7%)   0.147
  Quintile 2                     189 (20.1%)                           27 (16.9%)           162 (20.7%)        12 (20.0%)       177 (20.1%)                                       
  Quintile 3                     182 (19.3%)                           29 (18.1%)           153 (19.6%)         8 (13.3%)       174 (19.7%)                                       
  Quintile 4                     202 (21.4%)                           37 (23.1%)           165 (21.1%)        13 (21.7%)       189 (21.4%)                                       
  Quintile 5                     216 (22.9%)                           43 (26.9%)           173 (22.1%)        21 (35.0%)       195 (22.1%)                                       
  Physically active              674 (71.9%)                           108 (67.5%)          566 (72.8%)           0.179         46 (76.7%)          628 (71.5%)         0.392     
  Smokers (current)              105 (11.2%)                           23 (14.5%)            82 (10.5%)           0.153         10 (16.7%)          95 (10.8%)          0.166     
  Alcohol consumption (g/day)    12.4 (2.2, 28.8)                   17.3 (2.0, 34.3)      11.9 (2.2, 28.3)        0.156      20.3 (2.8, 28.7)    12.0 (2.8, 28.7)       0.179     
  Musculoskeletal disease        706 (77.0%)                           123 (79.4%)          583 (76.5%)           0.443         47 (79.7%)          659 (76.8%)         0.614     
  Thyroid disorders              21 (2.2%)                              4 (2.5%)             17 (2.2%)            0.799          4 (6.7%)            17 (1.9%)          0.016     
  Metabolic risk factors         665 (74.3%)                           107 (72.8%)          558 (74.6%)           0.646         46 (79.3%)          619 (74.0%)         0.367     
  GORD                           124 (13.2%)                           29 (18.1%)            95 (12.1%)           0.042         16 (26.7%)          108 (12.2%)         0.001     
  Gastrointestinal disorders     164 (17.4%)                           31 (19.4%)           133 (17.0%)           0.472         16 (26.7%)          148 (16.8%)         0.051     
  Recurrent headaches            50 (5.3%)                              15 (9.4%)            35 (4.5%)            0.012          2 (3.3%)            48 (5.4%)          0.481     
  Syncope and seizures           157 (16.7%)                           37 (23.1%)           120 (15.4%)           0.016         12 (20.0%)          145 (16.4%)         0.474     
  Cardiovascular disease         598 (68.5%)                           91 (65.5%)           507 (69.1%)           0.401         34 (63.0%)          564 (68.9%)         0.366     
  Pulmonary disease              All                                   178 (18.9%)               \-                \-                               11 (18.3%)       167 (18.9%)   0.908
  \<60 years old                 90/478 (18.8%)                      19/109 (17.4%)        71/369 (19.2%)         0.671             \-                  \-               \-       
  ≥60 years old                  88/464 (19.0%)                       18/51 (35.3%)         70/416 (17%)          0.002             \-                  \-               \-       
  Liver disorders                55 (5.8%)                              16 (10%)              39 (5%)             0.014          3 (5.0%)            52 (5.9%)          0.775     
  Cancer                         162 (17.2%)                           20 (12.5%)           142 (18.2%)           0.084          8 (13.3%)          154 (17.5%)         0.412     
  Psoriasis                      41 (4.3%)                              9 (5.6%)             32 (4.1%)            0.387          5 (8.3%)            36 (4.1%)          0.118     
  High medical burden            548 (62.2%)                           90 (62.9%)           458 (62.1%)           0.843         40 (70.2%)          508 (61.7%)         0.199     

Values are given as median (interquartile range) or number (%). Missing data: BMI, number = 28; physically active, number = 4; smokers, number = 5; musculoskeletal disease, number = 25; metabolic risk factors, number = 47; cardiovascular disease, number = 69; high medical burden, number = 61. GORD, gastro oesophageal reflux disease; IRSAD, Index of Relative Socioeconomic Advantage/Disadvantage.

Mood disorder
-------------

After adjustments for age, mood disorder was associated with increased odds of GORD (OR 2.41, 95% CI 1.48 to 3.00, *P* = 0.027), recurrent headaches (OR 2.46, 95% CI 1.29 to 4.69, P = 0.007), syncope and seizures (OR 2.41, 95% CI 1.31 to 3.09, *P* = 0.002) and liver disorders (OR 2.41, 95% CI 1.40 to 4.98, *P* = 0.003). Furthermore, a history of mood disorder was associated with increased odds of high medical burden (age-adjusted OR 1.80, 95% CI 1.16 to 2.77, *P* = 0.008). Mood disorders tended to be associated with musculoskeletal disease (OR 1.43, 95% CI 0.93 to 2.21, *P* = 0.104) and gastrointestinal disorders (OR 1.47, 95% CI 0.93 to 2.30, *P* = 0.096). Age was an effect modifier in the association between mood disorders and pulmonary disease. Among older men (≥60 years), a lifetime history of mood disorder was associated with increased odds of pulmonary disease (age-adjusted OR 2.75, 95% CI 1.45 to 5.21, *P* = 0.002); no association was detected for those younger than 60 years (*P* \>0.05). These relationships remained significant after further adjustment for BMI, SES, physical activity, alcohol consumption and smoking status (Table [2](#T2){ref-type="table"}). No association was observed between mood disorders and thyroid disorders, metabolic risk factors, cardiovascular disease, cancer and psoriasis.

###### 

Age-adjusted (model I) and fully-adjusted (model II) odds ratios for medical comorbidities in men with lifetime history of mood and anxiety disorders

                                       **Mood disorders**   **Anxiety disorders**                                                                
  ---------------------------- ------ -------------------- ----------------------- --------- ----------------- ---------------- ---------------- -------
  Musculoskeletal disease      I              1.43             (0.93 to 2.21)        0.104         1.39         (0.72 to 2.71)       0.328       
  II                           1.47      (0.94 to 2.31)             0.092            1.70     (0.85 to 3.43)        0.135                        
  Thyroid disorders            I              1.64             (0.52 to 5.12)        0.396         5.29         (1.63 to 7.14)       0.005       
  II                           1.81      (0.56 to 5.83)             0.321            5.54     (1.64 to 18.64)       0.006                        
  Metabolic risk factors       I              1.30             (0.85 to 1.99)        0.234         1.92         (0.96 to 3.83)       0.066       
  II^a^                        1.29      (0.83 to 2.00)             0.265            2.20     (1.07 to 4.53)        0.032                        
  GORD                         I              2.41             (1.48 to 3.00)       \<0.001        3.84         (2.01 to 7.33)      \<0.001      
  II                           2.67      (1.60 to 4.47)            \<0.001           4.25     (2.18 to 8.26)       \<0.001                       
  Gastrointestinal disorders   I              1.47             (0.93 to 2.30)        0.096         2.22         (1.20 to 4.10)       0.011       
  II                           1.46      (0.91 to 2.34)             0.112            2.40     (1.28 to 4.50)        0.006                        
  Recurrent headaches          I              2.46             (1.29 to 4.69)        0.007         0.63         (0.15 to 2.69)       0.537       
  II                           2.53      (1.30 to 4.96)             0.007            0.67     (0.16 to 2.89)        0.592                        
  Syncope and seizures         I              2.01             (1.31 to 3.09)        0.002         1.46         (0.75 to 2.85)       0.263       
  II                           2.01      (1.28 to 3.16)             0.002            1.55     (0.78 to 3.07)        0.207                        
  Cardiovascular disease       I              1.27             (0.82 to 1.93)        0.292         1.93         (0.60 to 2.13)       0.708       
  II                           1.28      (0.82 to 2.01)             0.276            1.15     (0.59 to 2.25)        0.678                        
  Pulmonary disease            All             I                     \-               \-            \-               0.95        (0.48 to 1.86)   0.874
  II                           \-              \-                    \-              1.02     (0.51 to 2.03)        0.956                        
  \<60 years old               I              0.90             (0.52 to 1.58)        0.725          \-                \-               \-        
  II                           1.01      (0.57 to 1.79)             0.971             \-            \-                \-                         
  ≥60 years old                I              2.75             (1.45 to 5.21)        0.002          \-                \-               \-        
  II                           2.65      (1.34 to 5.21)             0.005             \-            \-                \-                         
  Liver disorders              I              2.64             (1.40 to 4.98)        0.003         0.97         (0.29 to 3.24)       0.964       
  II                           3.03      (1.57 to 5.83)             0.001            1.03     (0.30 to 3.46)        0.967                        
  Cancer                       I              0.95             (0.56 to 1.61)        0.839         1.03         (0.47 to 2.29)       0.933       
  II                           0.90      (0.52 to 1.56)             0.706            1.03     (0.46 to 2.32)        0.938                        
  Psoriasis                    I              1.63             (0.75 to 3.55)        0.219         2.44         (0.91 to 6.57)       0.076       
  II                           1.41      (0.51 to 2.91)             0.648            2.77     (1.00 to 7.67)        0.049                        
  High medical burden          I              1.80             (1.16 to 2.77)        0.008         2.82         (1.43 to 5.53)       0.003       
  II^a^                        1.86      (1.19 to 2.91)             0.007            3.23      (1.61 to6.47)        0.001                        

^a^Model not adjusted for BMI as it is recorded in the medical condition. Model I -- Age-adjusted; Model II -- Fully-adjusted including: age, BMI, SES, physical activity, smoking and alcohol consumption. BMI, body mass index; CI, confidence interval; GORD, gastro oesaphogeal reflux disease; SES, socioeconomic status.

Anxiety disorder
----------------

After adjustment for age, anxiety disorder was associated with increased likelihood of thyroid disease (OR 5.29, 95% CI 1.63 to 7.14, *P* = 0.005), GORD (OR 3.84, 95% CI 2.01 to 7.33, *P* \<0.001), gastrointestinal disease (OR 2.22, 95% CI 1.20 to 4.10, *P* = 0.011) and high medical burden (OR 2.82, 95% CI 1.43 to 5.53, *P* = 0.003). Anxiety disorder also tended to be associated with metabolic risk factors (OR 1.92, 95% CI 0.96 to 3.83, *P* = 0.066). Further adjustment for BMI, SES, physical activity, alcohol consumption and smoking status did not affect these outcomes (Table [2](#T2){ref-type="table"}). The relationship between lifetime anxiety disorder and metabolic risk factors and lifetime anxiety disorders and psoriasis reached significance following adjustment for age, BMI, SES, physical activity, alcohol consumption and smoking status (OR 2.20, 95% CI 1.07 to 4.53, *P* = 0.032 and OR 2.77, 95% CI 1.00 to 7.67, *P* = 0.049, respectively). There were no associations detected between anxiety disorders and musculoskeletal disease, recurrent headaches, syncope and seizures, cardiovascular disease, pulmonary disease, liver disorders or cancer.

Discussion
==========

Our population-based study reports associations between mood and anxiety disorders and physical illness. Mood disorders were associated with increased risk of many of the disease groups (GORD, neurological features, such as recurrent headaches and syncope and seizures, liver disorders and pulmonary diseases in older men). Anxiety disorders presented a different profile; thyroid disorders, GORD, gastrointestinal disease, metabolic risk factors, and psoriasis were more common among individuals with anxiety disorder. Importantly, mood and anxiety disorders were both associated with high medical burden.

Our results confirm other population-based data investigating the association between mood disorder and GORD \[[@B60],[@B61]\]. In a sample of over 60,000 participants residing in Norway, those identified with depressive, anxiety and comorbid symptoms, as measured by the Hospital Anxiety and Depression Scale, had a two- to three-fold increased risk of reflux symptoms, self-reported severe symptoms of recurrent heartburn or acid regurgitation \[[@B62]\]. Moreover, mood disorders have also been shown consistently to be more prevalent in patients with GORD in clinical practice \[[@B15],[@B63]\].

Chronic headaches are high prevalence disorders, with as many as 46% of the adult population reporting headaches, 11% migraines and 42% tension headaches \[[@B64]\]. Similar to our findings and other population-based studies \[[@B65],[@B66]\], Scott *et al*. \[[@B24]\] utilising data pooled from 18 general population surveys reported those identified with either non-comorbid depression or comorbid depression and anxiety, as measured by the Composite International Diagnostic Interview, had an age and gender adjusted odds ratio of 2.5 and 4.0, respectively, for chronic headaches.

In regard to syncope and seizures, our results support Morgan *et al*. \[[@B67]\] who reported fainting, blackouts and dizziness, for which there is no adequate physical explanation, were associated with undiagnosed psychiatric disorders. Depression has also been shown to co-occur with epilepsy. Recently, the association has been viewed according to the diathesis-stress model, with depression resulting from the chronic stress associated with the threat of recurring seizures, as there is little evidence linking specific epilepsy related factors (for example, focus site) to low mood \[[@B68]\].

Akin to our results, Wilhelm and colleagues \[[@B69]\] reported an association between depression and liver pathology in a population-based survey of 10,641 adults; however, the relationship was not sustained following adjustment for demographic and behavioural confounders including drinking behaviour. Excessive alcohol consumption is known to be highly correlated with liver disease \[[@B21]\]; however, the association persisted following correction for alcohol in our study.

In our sample, only older men with a mood disorder were at increased risk of pulmonary disease. Although the association between asthma and mood disorder is evident across the full adult age range \[[@B23]\], chronic bronchitis and emphysema are more common among older people and most likely contribute to the different pattern observed for older and younger men. Furthermore, pulmonary disease can be considered in stages reflecting severity, a factor we could not explore \[[@B70]\].

Musculoskeletal and gastrointestinal disorders tended to be associated with mood disorders, although we speculate that the heterogeneous groupings we employed may have diluted associations in our sample population. Mood disorders and symptomology have previously been shown to be associated with low BMD and subsequent fracture, where both biological and medication related processes are thought to play a role \[[@B71]\]. Similarly, mood disorders have been shown to be associated with gastrointestinal disorders in both clinical and population-based samples \[[@B72]-[@B74]\].

In contrast to other population-based studies, we did not detect a relationship between mood disorders and thyroid disorders, metabolic risk factors, cardiovascular disease, cancer and psoriasis in this sample of men. The link between mood disorders and cardiovascular disease, thyroid disorders and metabolic risk factors, in particular, is well documented \[[@B22],[@B24],[@B30]\]. We hypothesize that these results may be influenced by a healthy participant bias, a common issue where study participants are required to be healthy enough to attend the research centre. Furthermore, disease grouping and data collection limited our ability to identify the degree of illness severity (that is, severe stroke, TIA and medically controlled hypertension were grouped) or time since onset of the physical condition.

As with mood disorders, GORD and gastrointestinal disorders were also associated with anxiety disorders. Anxiety has been previously considered to be a non-disease related factor that impacts negatively on quality of life associated with GORD \[[@B75]\] and, as previously discussed, is commonly observed within population-based samples reporting GORD symptoms \[[@B62]\]. Furthermore, data from the present study concur with previous studies indicating that those with anxiety disorder have higher rates of gastrointestinal disorders \[[@B34]\].

Psoriasis has been previously associated with anxiety disorders. Harter and colleagues \[[@B34]\] demonstrated that patients with a lifetime history of generalised anxiety disorder or panic disorder reported significantly higher lifetime prevalence rates for dermatological disorders, including psoriasis. Why this association is seen with anxiety disorders only in our sample population is unclear.

Thyroid disorders and metabolic risk factors have also been associated with anxiety disorders. In our study, anxiety was linked to a combination of the most common risk factors for metabolic disorders, such as hypertension, diabetes, hypercholesterolemia and obesity, which Culpepper and colleagues reported to be all likely due to a prolonged stress response in patients with untreated anxiety disorder \[[@B2]\]. Similarly, Simon *et al*. \[[@B35]\] reported an increased risk of thyroid disorders in patients with generalised anxiety disorder, social phobia or panic disorder and recommended screening for thyroid dysfunction in patients with anxiety disorders.

Our data suggest that both mood and anxiety disorders are associated with overall medical burden. These findings are consistent with previous studies showing both depression and anxiety to be associated with an increased number of somatic conditions \[[@B5],[@B76]\]. It is plausible that this relationship may be due to mood and anxiety disorders causing physiological changes, as well as poorer self-care and treatment adherence, which in turn increase medical burden \[[@B36]\]. On the other hand, an increased physical burden, causing functional impairment, may result in the development of an anxiety and/or mood disorder, which have been shown to have a negative impact on clinical outcomes \[[@B77]\].

A major strength of our study is that the sample population spans the full adult age range, in contrast to previous studies that have mainly focused on older patients. An age interaction was only evident when exploring the association between mood disorders and pulmonary disease; thus the relationship between mental illness and each of the physical conditions was consistent across all ages. Further strengths of the study include the measurement of mood and anxiety disorders, diagnoses were made utilising semi-structured clinical interviews (SCID-IV), a gold standard tool, and the consideration of several possible confounding factors. However, our observations must be considered with caution. Ascertaining medical conditions by a self-report checklist may be compromised by imperfect recall and response bias error. Although many of these disorders were based on self-report of a physician's diagnosis, which have been demonstrated to generally agree with medical record data \[[@B78]\], where possible this was confirmed by medical records, medication use or clinical data. The cross-sectional nature of the study does not allow verification of a cause-effect relationship between mental and physical illness, longitudinal studies are needed to determine the directionality of this relationship. Finally, we were unable to make a distinction between diseases with an episodic course and those with ongoing symptoms, which may impact differently on psychological status.

Conclusion
==========

Our study provides further population-based evidence supporting the link between mental and physical illness in men. Recognising the link between these illnesses is important in order to manage the development of mood and anxiety disorders in response to a medical condition, or the presence of physical pathologies due to predisposing psychiatric disorders. Integrating treatment approaches and monitoring comorbidity of mental and physical illnesses is likely to improve disease course and outcome as well as enhance patients' functional and health status, potentially reducing healthcare utilisation.
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